Phase II Trial of CRLX101 + Bevacizumab in Relapsed Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 06 May 2015
Price : $35 *
At a glance
- Drugs Camptothecin (Primary) ; Bevacizumab
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Cerulean Pharma
- 06 May 2015 According to a Cerulean Pharma media release, updated results from this trial are expected later in 2015.
- 19 Mar 2015 Interim clinical data published in the Media Release.
- 12 Feb 2014 New trial record